You are here

  • Home
  • Online First
  • Response to: ‘Correspondence on ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis’’ by Jeny et al

Article Text

Article menu

other Versions

Download PDFPDF
Correspondence response
Response to: ‘Correspondence on ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis’’ by Jeny et al
  1. Andrea Hermina Györfi,
  2. Georg Schett,
  3. Jörg H W Distler
  1. Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany
  1. Correspondence to Prof. Jörg H W Distler, Department of Internal Medicine III, University of Erlangen, Erlangen D-91054, Germany; joerg.distler{at}uk-erlangen.de

https://doi.org/10.1136/annrheumdis-2020-218983

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Cohen Aubart et al for their correspondence.1 Their study on 36 patients with sarcoidosis and COVID-19 from 15 French centres provides interesting insights on the outcome of COVID-19 in this group of patients. These data provide evidence that a higher percentage of patients with sarcoidosis with COVID-19 might require intensive care support than in the general population. In contrast, sarcoidosis does not seem to affect the severity of COVID-19, and patients with sarcoidosis-associated interstitial lung disease (ILD) are not admitted more often to the intensive care unit (ICU) than patients without ILD.

    The data by Cohen Aubart et al1 show that 85% of the patients with sarcoidosis with COVID-19 admitted to …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Contributors All authors contributed to drafting and revising the article and approved the final version.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests JHWD is involved in the development of new targeted therapies for fibrotic diseases such as systemic sclerosis. JHWD has consultancy relationships with Actelion, Active Biotech, Anamar, ARXX, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, JB Therapeutics, Medac, Pfizer, RuiYi and UCB. JHWD has received research funding from Anamar, Active Biotech, Array Biopharma, aTyr, BMS, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, Novartis, Sanofi-Aventis, RedX and UCB. JHWD is stock owner of 4D Science and Scientific head of FibroCure.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Patient consent for publication Not required.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles

    • Correspondence
      Correspondence on ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis’
      Florence Jeny Raphael Lhote Gwenael Lorillon Nicolas Belhomme Grégory Pugnet Raphaël Borie Aurélien Justet Stephane Jouneau Nathalie Freymond Arsène Mekinian Robin Dhote Yacine Tandjaoui-Lambiotte Nathalie Saindenberg Pierre Gazengel Baptiste Hervier Julien Haroche Alexis Mathian Miguel Hié Thibaud Chazal Dov Taieb Yurdagul Uzunhan Jérôme Le Pavec Isabella Annesi-Maesano Emmanuel Bergot Abdellatif Tazi Zahir Amoura Dominique Valeyre Hilario Nunes Fleur Cohen-Aubart
      Annals of the Rheumatic Diseases 2020; 81 e241-e241 Published Online First: 01 Oct 2020. doi: 10.1136/annrheumdis-2020-218957